The application of polydeoxyribonucleotides  in the treatment of diabetes

Hao Xu

doi:10.54097/20kteq70

Authors

Hao Xu

DOI:

https://doi.org/10.54097/20kteq70

Keywords:

Polydeoxyribonucleotides; medicine; diabetes.

Abstract

Polydeoxynucleotides (PDN) are a particular kind of DNA fragment found in the sperm liquid of the salmon. PDN is so close to the human DNA, over 98%. It’s very, very important for science and medicine. PDN is a A2A receptor agonist that can help to stop the effect of inflammation, and it’s used for different kinds of inflammatory sicknesses.The main functions can be classified as promoting tissue repair, wound healing, treating angiogenesis, anti-inflammation and immune regulation, as well as anti-ischemic effects. And it is also proved to promote the cell proliferation and vascular regeneration, so it hasobvious effects in tissue repair and anti-ischemia. PDN is also involved in diabetes.With the development of synthetic biology and delivery technology, the application prospects of PDRN will be even broader, and it is expected to become an important drug in the treatment of diabetic complications This article will explore the medicinal value of PDRN, current research, and breakthroughs in clinical applications.

Downloads

Download data is not yet available.

References

[1] CORRIERE M, ROOPARINESINGH N, KALYANI RR. Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health issue. Curr Diab Rep. 2013;13(6):805–813. DOI: https://doi.org/10.1007/s11892-013-0425-5

[2] WILD S, ROGLIC G, GREEN A, SICREE R, KING H. Global estimates of the prevalence of diabetes for 2000 and 2030. Diabetes Care. 2004;27(5):1047–1053. doi:10.2337/diacare.27.5.1047. DOI: https://doi.org/10.2337/diacare.27.5.1047

[3] NOH J. Diabetes epidemic in Korea. Endocrinol Metab. 2016;31(3):349–353. doi:10.3803/EnM.2016.31.3.349. DOI: https://doi.org/10.3803/EnM.2016.31.3.349

[4] MAFFI P, SECCHI A. The burden of diabetes: emerging data. Dev Ophthalmol. 2017;60:1–5. doi:10.1159/000457123. DOI: https://doi.org/10.1159/000459641

[5] LIU Y, LIU Y, DENG J, LI W, NIE X. Fibroblast growth in diabetic foot ulcer: progress and therapeutic prospects. Front Endocrinol (Lausanne). 2021;12:744868. doi:10.3389/fendo.2021.744868. DOI: https://doi.org/10.3389/fendo.2021.744868

[6] XIAO J, LI J, CAI L, CHAKRABARTI S, LI X. Cytokines and diabetes research: a comprehensive review. J Diabetes Res. 2014;2014:920613. doi:10.1155/2014/920613. DOI: https://doi.org/10.1155/2014/920613

[7] LAN CC, LIU IH, FANG AH, WEN CH, WU CS. Hyperglycaemic conditions decrease cultured keratinocyte mobility: implications for impaired wound healing in diabetes. Br J Dermatol. 2008;159(5):1103–1115. doi:10.1111/j.1365-2133.2008.08784.x. DOI: https://doi.org/10.1111/j.1365-2133.2008.08789.x

[8] MAIONE AG, SMITH A, KASHPUR O, YANEZ V, KNIGHT E, MOONEY DJ, VEVES A, TOMIC-CANIC M, GARLICK JA. Diabetic foot ulcer-derived fibroblasts alter ECM deposition implicating fibronectin in chronic wound repair. Wound Repair Regen. 2016;24(4):630–643. doi:10.1111/wrr.12442. DOI: https://doi.org/10.1111/wrr.12437

[9] BOULTON AJ. The pathway to foot ulceration in diabetes. Med Clin North Am. 2013;97(5):775–790. doi:10.1016/j.mcna.2013.05.002. DOI: https://doi.org/10.1016/j.mcna.2013.03.007

[10] DINH TL, VEVES A. A review of the mechanisms involved in the pathogenesis of diabetic foot ulcers. Int J Low Extrem Wounds. 2005;4(3):154–159. doi:10.1177/1534734605279864. DOI: https://doi.org/10.1177/1534734605280130

[11] E. Marasco1, R. Nicolai1, A. Ariolli1,et al. Proceedings of the 32nd European Paediatric Rheumatology Congress. Pediatric Rheumatology, 2025, 23(93). DOI: https://doi.org/10.1186/s12969-025-01138-8

[12] E. Raposio , C. Guida , R. Coradeghini , C. Scanarotti , et al. In vitropolydeoxyribonucleotide effects on human pre-adipocytes. Cell Proliferation.